The approval was based on data from the 2 randomized clinical studies that assessed StrataGraft in a total of 101 adults with deep partial thickness thermal burns. The Food and Drug Administration ...

Please provide your email address to receive an email when new articles are posted on . NexoBrid was approved for the treatment of deep partial-thickness and full-thickness thermal burns in adults in ...

STAINES-UPON-THAMES, United Kingdom, Sept. 23, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced positive top-line results from its pivotal Phase 3 ...

Credit: Getty Images. NexoBrid is a topically administered, bromelain-based biological product containing a sterile mixture of proteolytic enzymes. The Food and Drug Administration (FDA) has approved ...

The US Food and Drug Administration (FDA) has approved a novel regenerative therapy that could be an alternative to autografting for treating adults with severe burns. The new treatment, StrataGraft, ...

- First publication of full data set shows use of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) eliminated autografting in 96% of burn sites treated ...

Mallinckrodt plc, a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft ®, an investigational regenerative tissue, in Burns, ...

Cohealyx® multi-center study interim analysis and new case data to be presentedRECELL® and PermeaDerm® data reinforce a comprehensive approach to ...

The External Assessment Centre excluded all the studies identified by the sponsor because they were outside the scope of the evaluation, although it did recognise that the studies contained useful ...